We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » At Public Meeting, Biosimilars Industry Lets FDA Know What’s Still Lacking in Its Communications
At Public Meeting, Biosimilars Industry Lets FDA Know What’s Still Lacking in Its Communications
The FDA’s communications with the biosimilars industry around inspection delays have been “poor,” and its interaction with that sector of the industry around application-level communications and regulatory science hasn’t been much better.